

Preliminary Screening of *in vitro* *Kaempferia galanga* Oil for Anti-Proliferative Activities Against HeLa and MCF-7 Cell

Pharmacognosy Magazine

19(3) 660–666, 2023

© The Author(s) 2023

Article reuse guidelines:

in.sagepub.com/journals-permissions-india

DOI: 10.1177/09731296231172544

journals.sagepub.com/home/phm

Rajashree Panigrahi¹ and Reena Parida¹

Abstract

Background: *Kaempferia galanga*, commonly known as aromatic ginger, is a potential herb with high medicinal value and is used to treat many diseases like diabetes and asthma. Cancer is a group of diseases characterized by abnormal cells that divide uncontrollably and spread throughout the body. Nowadays, medicinal plants are used for their essential oil activities, including anti-cancerous effects.

Objectives: The aim of this study is to establish a method for screening *in vitro* oil cytotoxic effects.

Materials and Methods: Murashige and Skoog (MS) medium with growth regulators like benzyladenine, kinetin, indole-3-acetic acid, adenine sulfate, and naphthalene acetic acid was used for plantlet production. The *in vitro* regenerated plants were studied for rhizome oil extraction using Clevenger's apparatus and gas chromatography-mass spectrometry (GC-MS) analysis, followed by their cytotoxicity study against human cervical cancer cells (HeLa) and human breast cancer cells (MCF-7) by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction (MTT) assay.

Results: Upon analysis, it has been found that this medicinal plant contains ethyl-p-methoxycinnamate (EPMC) ($56.41 \pm 0.34\%$) as a vital compound in its rhizome oil. The validation of cytotoxicity in both cell lines was done by treatment with rhizome oil concentrations ranging from 6.25 to 100 μL , respectively. The IC_{50} value was found to be $44.18 \pm 0.65 \mu\text{L/mL}$ in HeLa and $72.94 \pm 0.26 \mu\text{L/mL}$ in MCF-7 cells after 24 h of incubation.

Conclusion: The results of this study would be helpful for this important medicinal plant to be used by pharmaceuticals in the treatment of cancer.

Keywords

Kaempferia galanga, rhizome oil, gas chromatography-mass spectrometry, HeLa, MCF-7, MTT assay

Received 12 December 2022; accepted 28 February 2023

Introduction

Kaempferia galanga of the Zingiberaceae family emerges from tubed roots; the rhizome is almost white in color with a soft interior and has 4–5 dark green leaves that are slightly flattened. In India, it is widely distributed in states like Andhra Pradesh, Arunachal Pradesh, Assam, Kerala, Karnataka, Meghalaya, Manipur, Odisha, and West Bengal (Kumar, 2020). The English names of the studied plant samples are sand ginger, aromatic ginger, and lesser galanga. This plant is a good source of stimulant, expectorant, carminative, diuretic, and anti-pyretic remedies. It has shown potential to treat diseases like diabetes, hypertension, joint fractures, asthma, vertigo, and intestinal wounds (Khare, 2007; Manohar, 2012; Mukherjee, 2015; Seth & Maurya, 2014). Cancer is a large

group of diseases that affect all parts of the body. It occurs due to the alteration of normal cells into tumor cells in a step-by-step process and is the leading cause of death worldwide. The cases are increasing, mainly due to a lack of understanding by people and their ignoring of the early signs of cancer. With the advancement in technology and science, the mortality rate is reduced, but treatments like chemotherapy result in several

¹Molecular Biology and Genetic Engineering Laboratory, Centre for Biotechnology, Siksha 'O' Anusandhan University, Bhubaneswar, Odisha, India

Corresponding author:

Reena Parida, Molecular Biology and Genetic Engineering Laboratory, Centre for Biotechnology, Siksha 'O' Anusandhan University, Bhubaneswar, Odisha 751003, India.
E-mail: ms.reenas@gmail.com



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<http://www.creativecommons.org/licenses/by-nc/4.0/>) which permits non-Commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

side effects. To meet their healthcare needs, cancer patients believe in therapies within and outside of allopathic therapy. Also, the survey showed that many plant species have anticancer properties, one of which is *K. galanga*, whose plant parts are active against a few cancer cells, such as the human lung adenocarcinoma cell line (A549), the colon cancer cell line (COLO-201), the leukemia cell line (K562), and the human epidermal keratinocyte cell line (HaCaT).

Ethyl-p-methoxycinnamate (EPMC) is one of the major bioactive compounds present in this plant and has cytotoxicity on a number of cell lines (Jagadish et al., 2016; Umar et al., 2011). This plant is being used in the preparation of cosmetic products and as a spice. It has various biological activities such as being anti-nociceptive, anti-inflammatory, antioxidant, and is also used to treat migraines, mouth ulcers, rheumatism, and eye infections (Munda et al., 2018; Sulaiman et al., 2008). Reports on rhizome essential oil production are available, yet there are scanty reports on the *in vitro* oil cytotoxic activity of *K. galanga* (Vidya et al., 2021). The (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction (MTT) assay is the widely accepted method to measure cell metabolic activity, proliferation, viability, and cytotoxicity; hence, MTT assay was conducted. It is a colorimetric assay, which is based on the reduction of yellow tetrazolium salt to purple formazan crystals by metabolically active cells. The resulting solution absorbance is quantified at 500–600 nm using a multiwell spectrophotometer. Thus, the aim of this study was to study the essential oil cytotoxic effects from tissue culture-raised *K. galanga* rhizomes.

Materials and Methods

Sample Collection and Gas Chromatography-Mass Spectrometry Analysis

K. galanga plant samples were collected and explants in sterilized conditions were inoculated on Murashige and Skoog (MS) medium with growth regulators like benzyladenine, kinetin, indole-3-acetic acid, adenine sulfate, and naphthalene acetic acid, with agar (0.8%) and sucrose (30 g/L), following a previous standardized method for plantlet production (Mohanty et al., 2011; Parida et al. 2010). The *in vitro* regenerated plants with well-developed shoots and roots were transferred to the field for further growth to estimate the percentage of rhizome oil using a standardized protocol (Guenther, 1972). Approximately 500 g of *in vitro* *K. galanga* rhizomes were collected in the early morning from the institute's greenhouse. The Clevenger apparatus was used, in which 500 g of rhizome sample and 1,000 mL of sterile water were heated for 6 h for vapor collection by collecting chamber. Then compounds were identified by the gas chromatography-mass spectrometry (GC-MS) method using HP 6890 series GC coupled with a mass selective detector, HP 5973 series. The molecules were identified by the National Institute of

Standards and Technology (NIST) reference library using Mass Spectrum Interpreter Software, version 3.4.

Culturing of Cancer Cell Lines, Groups for Treatment with MTT Viability Assays

The human cervical cancer cells (HeLa) (National Centre for Cell Science, Pune, India) P-32 and human breast cancer cells (MCF-7) (National Centre for Cell Science, Pune, India) P-48 were collected for the present study. Assay controls were only medium, control negative as medium with cells, no experimental compound, control positive as medium with cells, and camptothecin as a standard drug (10 μ M). In Dulbecco's Modified Eagle Medium, cells were subcultured and supplied with a 10% fetal bovine serum, 1% penicillin-streptomycin, 1% glutamine, and incubated in a carbon dioxide (CO₂) incubator with carbon monoxide (CO) at 5% and a humidity of 95%. The trypan blue method was then used to determine cell count and viability using a hemocytometer. The 96-well plates were seeded with 200 μ L of cell suspension at cell density without cells, and the test agent was left for 24 h to grow. The test samples in 5 concentrations of 6.25, 12.5, 25, 50, and 100 μ L/mL were added and incubated at 37°C for 24 h in a 5% CO₂ atmosphere. Then spent media were removed from plates, and a final concentration of 0.5 mg/mL MTT reagent was added. The aluminum foil was used to wrap the plates to avoid light and then incubated for 3 h. After incubation, MTT reagent was removed and dimethyl sulfoxide (DMSO) of 100 μ L was added. The control and sample absorbance was done in an enzyme-linked immunosorbent assay (ELISA) reader at 630 nm with IC₅₀ value calculation using a linear regression equation from the graph (Gerlier & Thomasset, 1986; MTT, 2022). All the data provided in the experiment were performed on duplicate samples.

Results and Discussion

The rhizome essential oil yield in the field-grown plants was $0.8 \pm 0.04\%$, which was transparent in color (Figure 1). A total of 13 compounds were identified, accounting for 100% of the total oil. The rhizome essential oil of *K. galanga* was predominated by ethyl p-methoxycinnamate ($56.41 \pm 0.34\%$). Besides ethyl p-methoxycinnamate, 2-propenoic acid, 3-phenyl, ethyl ester ($21.95 \pm 0.31\%$), 3-carene ($6.77 \pm 0.25\%$), and eucalyptol ($5.58 \pm 0.23\%$) were found to be the other major constituents in the tested essential oil (Table 1, Figure 2). In the study of anti-proliferative activities, positive control as camptothecin, different drug concentrations of oil samples (6.25, 12.5, 25, 50, and 100 mg/mL) against HeLa and MCF-7 cells with viability percentages have been given in Table 2, Figures 3 and 4. The IC₅₀ value of *K. galanga* oil in HeLa was found to be $44.18 \pm 0.65 \mu$ L/mL in 24 h and $9.89 \pm 0.53 \mu$ L/mL in 48 h. Similarly, the IC₅₀ value in MCF-7 was




Figure 1. The Tissue Cultured raised *K. galanga* Plantlets (A) In *in vitro* Condition (B) In Field Condition Maintained for Extraction of Rhizome Essential Oil.

Note: *K. galanga*, *Kaempferia galanga*.

Table 1. Chemical Composition by GC-MS Analysis of Rhizome Essential Oil in *K. galanga*.

Peak No.	Retention Time	Oil Constituents	Molecular Formula	Area (%)
1	6.06	3-Carene	$C_{10}H_{16}$	6.77 ± 0.25
2	6.665	Eucalyptol	$C_{10}H_{18}O$	5.58 ± 0.23
3	9.063	Hydroxy- α -terpenyl acetate	$C_{12}H_{20}O_3$	0.33 ± 0.14
4	11.274	Borneol	$C_{10}H_{18}O$	1.99 ± 0.26
5	12.162	Thymol	$C_{10}H_{14}O$	1.10 ± 0.31
6	16.006	Bornyl acetate	$C_{12}H_{20}O_2$	0.13 ± 0.40
7	23.309	2-Propenoic acid, 3-phenyl-, ethyl ester	$C_{11}H_{12}O_2$	21.95 ± 0.31
8	24.628	Pentadecane	$C_{15}H_{32}$	3.15 ± 0.02
9	26.527	γ -Elemene	$C_{15}H_{24}$	0.47 ± 0.09
10	28.798	Naphthalene, 1,2,3,4,4a,7-hexahydro-1,6-dimethyl-4-(1-methylethyl)-	$C_{15}H_{24}$	0.58 ± 0.04
11	30.269	α -Cadinol	$C_{15}H_{26}O$	0.58 ± 0.93
12	31.474	3,4-Octadiene, 7-methyl-	C_9H_{16}	0.98 ± 0.02
13	34.147	Ethyl p-methoxycinnamate	$C_{12}H_{14}O_3$	56.41 ± 0.34

Abbreviations: *K. galanga*, *Kaempferia galanga*; GC-MS, gas chromatography-mass spectrometry.





Figure 2. The GC-MS Chromatogram of *K. galanga* Rhizome Essential Oil.

Note: GC-MS, gas chromatography-mass spectrometry.


Table 2. Viability Percentage of Camptothecin with HeLa and MCF-7 Against *K. galanga* Rhizome Oil.

Untreated	Standard (Camptothecin)	Standard (Camptothecin)	Incubation (h)	Different Concentration	HeLa cell (μ L)	MCF-7 cell (μ L)
100	50.5	50.91	24	6.25	97.93	85.37
				12.5	82.19	76.69
				25	73.75	65
				50	41.06	55.04
				100	28.11	45.49
100	22.24	38.17	48	6.25	58.42	76.21
				12.5	46.13	66.75
				25	32.31	58.45
				50	16.93	42.61
				100	6.58	29.86

Abbreviations: HeLa, human cervical cancer cell; MCF-7, human breast cancer cell; *K. galanga*, *Kaempferia galanga*.

**Figure 3.** The Effect of *K. galanga* Rhizome Oil on HeLa Cell after Treatment of (1) 24 and (2) 48 hours.

Note: HeLa, human cervical cancer cell; MTT assay, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay.

**Figure 4.** The Effect of *K. galanga* Rhizome Oil on MCF-7 Cell after Treatment of (1) 24 and (2) 48 hours.

Note: MCF-7, human breast cancer cells; MTT assay, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay.




Figure 5. Cell Viability analysis by MTT Assay showing effect of *K. galanga* Rhizome Oil on HeLa Cell at 24 and 48 hours of Incubation.

Note: HeLa, human cervical cancer cell; MTT assay, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay; *K. galanga*, *Kaempferia galanga*.




Figure 7. Cell Viability analysis by MTT Assay showing effect of *K. galanga* Rhizome Oil on MCF-7 Cell at 24 and 48 hours of Incubation.

Note: MCF-7, human breast cancer cells; MTT assay, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay; *K. galanga*, *Kaempferia galanga*.




Figure 6. Microscopic Observation of HeLa Cell after *K. galanga* Rhizome Oil Treatment (1) HeLa Control (2) 10 μ M of Camptothecin as Standard (Positive Control) (3, 4) HeLa Cell Activity in *K. galanga* Rhizome Oil in Concentration of 6.25 μ L/mL (5, 6) 12.5 μ L/mL (7, 8) 25 μ L/mL (9, 10) 50 μ L/mL (11, 12) 100 μ L/mL of samples after 24 and 48 hours of Incubation Period.

Note: HeLa, human cervical cancer cell; *K. galanga*, *Kaempferia galanga*.




Figure 8. Microscopic Observation of MCF-7 Cells after *K. galanga* Rhizome Oil Treatment (1) MCF-7 Control (2) 10 μ M of Camptothecin as Standard (Positive Control) (3, 4) MCF-7 Cell Activity in *K. galanga* Rhizome Oil in Concentration of 6.25 μ L/mL (5, 6) 12.5 μ L/mL (7, 8) 25 μ L/mL (9, 10) 50 μ L/mL (11, 12) 100 μ L/mL of samples after 24 and 48 hours of Incubation Period.

Note: MCF-7, human breast cancer cells; *K. galanga*, *Kaempferia galanga*.

found to be 72.94 ± 0.26 μ L/mL in 24 h and 33.41 ± 0.31 μ L/mL in 48 h. The 50% HeLa reduction against oil concentrations was effective by MTT assay (Figures 5 and 6). Similarly, MTT assays revealed the effectiveness of the concentration required for 50% of MCF-7 reduction in oil concentrations (Figures 7 and 8).

There are several studies reported on GC-MS analysis of this plant in which ethyl p-methoxycinnamate was found to be the major compound as ours, and we have also reported earlier the same in *K. galanga* (Ajay, 2014; Mohanty et al., 2011; Raina & Abraham, 2016). Some reports are available

on the extensive use of *K. galanga* rhizome extract medicinally as food for its aromatic flavor and other nutritional benefits (Umar et al., 2011). Most of the pharmacological properties found in *K. galanga* rhizome are due to the presence of EPMC and ethyl-cinnamate as the most vital constituents. There are antitumor properties in *K. galanga* rhizome extract, which has shown anti-proliferative potential in nine human cancer cells (Srivastava et al., 2019). In their study, *K. galanga* rhizome was demonstrated as a safe and high-energy medicinal spice with chemo-preventive action and without any toxic

phytochemicals. Similarly, our study is in its favor, but we have shown the effects of using rhizome essential oils. There are studies on the antineoplastic activity of EPMC present in *Kaempferia*, which has proven to have potential in the treatment of oral cancer (Ali et al., 2018; Ichwan et al., 2019; Ichwan et al., 2020). They have examined EPMC, the major constituent of *K. galanga*, in human lung adenocarcinoma cells. Their study showed EPMC stimulates cytotoxic and apoptotic effects on lung cancer cells. So also in our study, EPMC, being the major constituent in *in vitro* rhizome oil, might be responsible for anticancer effects against human cervical and breast cancer cells. Other reports are available on the cytotoxic effects of *K. galanga* essential oil and extracts on the cervical cancer cell line (Omar et al., 2017). But we have studied the same in micropropagated rhizome essential oil. There are various recent reports on *K. galanga* rhizome extracts exhibiting antiinflammatory and anticarcinoma activities (Amuamuta et al., 2017; Atun, 2014; Dwita et al., 2021). They have studied the ethanolic extract of *K. galanga* rhizome, EPMC, and 5-fluorouracil for their cytotoxicity against the CCA cell line using the MTT assay. It concluded that rhizome extract and its bioactive compound EPMC exhibited moderate cytotoxic activity against human CCA tumor cells. The results of others showed the highest level of EPMC in its rhizome extract using the GC-MS method, exhibiting significant anti-inflammatory activity.

Conclusion

The present study investigates the presence of ethyl p-methoxycinnamate as a major bioactive compound in rhizome essential oil, which might be helpful in the treatment of cancer cells. The oil composition and proportions are influenced by geographic, climatic, genotypic, and many other factors. So also, in the study, 50% of HeLa and MCF-7 showed reductions in rhizome oil concentrations, which were effective using the MTT assay. This method could explore drug preparation approaches by utilizing *in vitro* propagated rhizomes, thereby shortening the demand in the market. However, further studies should be done to evaluate the mechanisms of bioactive compounds that showed potential cytotoxic effects, thereby bioprospecting for cancer treatment. Thus, the outcome of the study would be of sufficient significance to develop a novel method for the extraction of essential oils from micropropagated rhizomes. In addition, the results of the cytotoxicity study of this important medicinal plant will enhance the commercial importance of its use by industries.

Summary

In *K. galanga* oil, ethyl p-methoxycinnamate was found to be the primary compound present in the *in vitro* field-grown plants.

Both HeLa and MCF-7 cell lines used against oil concentrations showed effective results by the MTT assay.

It also revealed that the essential oil could be further used by pharmaceuticals in the treatment of cancer cells.

Abbreviations

HeLa; human cervical cancer cell; MCF-7; human breast cancer cell; MTT assay; (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay; EPMC: ethyl-p-methoxycinnamate; *K. galanga*: *Kaempferia galanga*; MS medium; Murashige and Skoog medium; GC-MS: gas chromatography-mass spectrometry; NIST library; National Institute of Standards and Technology library; CO₂: carbon dioxide; CO: carbon monoxide; DMSO: dimethyl sulphoxide; ELISA: enzyme-linked immunosorbent assay.

Acknowledgments

The authors are grateful to Prof. (Dr.) M.R. Nayak, President and Prof. (Dr.) S.C. Si, Dean, Centre for Biotechnology, Siksha 'O' Anusandhan University, for providing facilities and encouraging throughout.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Statement of Informed Consent and Ethical Approval

Necessary ethical clearances and informed consent were obtained before initiating the study from all the participants.

Funding

The author received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Reena Parida  <https://orcid.org/0000-0001-8059-8417>

References

- Ajay, K. (2014). Chemical composition of essential oil isolated from the rhizome of *Kaempferia galanga* L. *International Journal of Pharmacy and Biological Sciences*, 5, 225–231.
- Ali, H., Yesmin, R., Satter, M. A., Habib, R., & Yeasmin, T. (2018). Antioxidant and antineoplastic activities of methanolic extract of *Kaempferia galanga* Linn. rhizome against Ehrlich ascites carcinoma cells. *Journal of King Saud University – Science*, 30(3), 386–392. <https://doi.org/10.1016/j.jksus.2017.05.009>
- Amuamuta, A., Plengsuriyakarn, T., & Na-Bangchang, K. (2017). Anticholangiocarcinoma activity and toxicity of the *Kaempferia galanga* Linn. rhizome ethanolic extract. *BMC Complementary and Alternative Medicine*, 17(1), 213. <https://doi.org/10.1186/s12906-017-1713-4>, PubMed: 28403856
- Atun, S. (2014). Phytochemical of *Kaempferia* plant and bioprospecting for cancer treatment. *Proceeding of International*

- Conference on Research, Implementation and Education of Mathematics and Science, 1–9.
- Dwita, L. P., Hikmawanti, N. P. E., Yeni, & Supandi. (2021). Extract, fractions and ethyl-p-methoxycinnamate isolate from *Kaempferia galanga* Elicit anti-inflammatory activity by limiting leukotriene B4 (LTB4) production. *Journal of Traditional and Complementary Medicine*, 11(6), 563–569. <https://doi.org/10.1016/j.jtcme.2021.06.004>
- Gerlier, D., & Thomasset, N. (1986). Use of MTT colorimetric assay to measure cell activation. *Journal of Immunological Methods*, 94(1–2), 57–63. [https://doi.org/10.1016/0022-1759\(86\)90215-2](https://doi.org/10.1016/0022-1759(86)90215-2)
- Guenther, E. (1972). The production of essential oils. In E. Robert (Ed.), *The essential oils* (pp. 361–391). New York: Krieger Publishing.
- Ichwan, S. J. A., Husin, A., Suriyah, W. H., Lestari, W., Omar, M. N., & Kasmuri, A. R. (2019). Anti-neoplastic potential of ethyl-p-methoxycinnamate of *Kaempferia galanga* on oral cancer cell lines. *Materials Today: Proceedings*, 16, 2115–2121. <https://doi.org/10.1016/j.matpr.2019.06.100>
- Ichwan, S. J. A., Sajeli, S., & Lestari, W. (2020). Analysis of the anticancer effect of ethyl-p-methoxycinnamate extracted cekur (*Kaempferia galanga*) on cancer cell lines with wild type and null p53. *IIUM Journal of Orofacial and Health Sciences*, 1(1), 28–33.
- Jagadish, P. C., Latha, K. P., Mudgal, J., & Nampurath, G. K. (2016). Extraction, characterization and evaluation of *Kaempferia galanga* L. (Zingiberaceae) rhizome extracts against acute and chronic inflammation in rats. *Journal of Ethnopharmacology*, 194, 434–439. <https://doi.org/10.1016/j.jep.2016.10.010>, PubMed: 27720847
- Khare, C. (2007). *Kaempferia galanga* Linn, *Indian medicinal plants* (pp. 717–718). New Delhi: Springer.
- Kumar, A. (2020). Phytochemistry, pharmacological activities and uses of Indian traditional medicinal plant *Kaempferia galanga* L. an Overview. *Journal of Ethnopharmacology*, 253, 112667.
- Manohar, M. (2012). *Ayurveda for all: Effective Ayurvedic self-cure for common and chronic ailments* (p. 115). V&S Publishers.
- Mohanty, S., Parida, R., Singh, S., Joshi, R. K., Subudhi, E., & Nayak, S. (2011). Biochemical and molecular profiling of micropropagated and conventionally grown *Kaempferia galanga*. *Plant Cell, Tissue and Organ Culture*, 106(1), 39–46. <https://doi.org/10.1007/s11240-010-9891-5>
- MTT Cell Proliferation Assay Instruction Guide. (2022). <http://www.atcc.org>. Retrieved November 28, 2022.
- Mukherjee, P. K. (2015). *Evidence based validation of herbal medicine* (pp. 13–14). Boston: Elsevier.
- Munda, S., Saikia, P., & Lal, M. (2018). Chemical composition and biological activity of essential oil of *Kaempferia galanga*: A review. *Journal of Essential Oil Research*, 30(5), 303–308. <https://doi.org/10.1080/10412905.2018.1486240>
- Omar, M. N., Rahman, S. M. M., Ichwan, S. J. A., Hasali, N. H. M., Rasid, F. A., & Halim, F. A. (2017). Cytotoxicity effects of extracts and essential oil of *Kaempferia galanga* on cervical cancer C33A cell line. *Oriental Journal of Chemistry*, 1659–1664.
- Parida, R., Mohanty, S., Kuanar, A., & Nayak, S. (2010). Rapid multiplication and *in vitro* production of leaf biomass in *Kaempferia galanga* through tissue culture. *Electronic Journal of Biotechnology*, 13(4), 1–8.
- Raina, A. P., & Abraham, Z. (2016). Chemical profiling of essential oil of *Kaempferia galanga* L. Germplasm from India. *Journal of Essential Oil Research*, 28, 29–34.
- Seth, A., & Maurya, S. K. (2014). Potential medicinal plants and traditional Ayurvedic approach towards urticaria, an allergic skin disorder. *International Journal of Pharmacy and Pharmaceutical Sciences*, 6, 172–177.
- Srivastava, N., Ranjana, Singh, S., Gupta, A. C., Shanker, K., Bawankule, D. U. & Luqman, S. (2019). Aromatic ginger (*Kaempferia galanga* L.) extracts with ameliorative and protective potential as a functional food, beyond its flavor and nutritional benefits. *Toxicology Reports*, 6, 521–528. <https://doi.org/10.1016/j.toxrep.2019.05.014>
- Sulaiman, M. R., Zakaria, Z. A., Daud, I. A., Ng, F. N., Ng, Y. C., & Hidayat, M. T. (2008). Antinociceptive and anti-inflammatory activities of the aqueous extract of *Kaempferia galanga* leaves in animal models. *Journal of Natural Medicines*, 62(2), 221–227. <https://doi.org/10.1007/s11418-007-0210-3>
- Umar, M. I., Asmawi, M. Z., Sadikun, A., Altaf, R., & Iqbal, M. A. (2011). Phytochemical and medicinal properties of *Kaempferia galanga* L. (Zingiberaceae) extracts. *African Journal of Pharmacy and Pharmacology*, 5(14), 1638–1647.
- Vidya, V. R., Hemanthakumar, A. S., Kumar, C. B. R., Pillai, P., & Preetha, T. S. (2021). *In vitro* microrhizome induction and essential oil production from aromatic ginger *Kaempferia galanga* L. An economically important medicinal herb. *Bioscience Biotechnology Research Communications*, 14(4), 1591–1599.